JPRN-UMIN000025997已完成未知
A study on the effectiveness of SRRA001(development code) - A study on the effectiveness of SRRA001(development code)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 59years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1.Individuals attending a hospital or using medical products 2.Individuals using medical products for pollinosis 3.Individuals who have chronic illness 4.Individuals who have a history of serious disease (heart disease, kidney damage, diabetes, cancer, and so on) 5.Individuals who are sensitive to medical tapes or electrodes 6.Individuals who participate in the other examinations which have an influence on this examination 7.Individuals judged inappropriate for the study by the principal
研究者
相似试验
已完成
不适用
A study on the effectiveness of USRP001(development code)Healthy adultsJPRN-UMIN000023443Kao Corporation15
已完成
不适用
A study on the effectiveness of USRP002(development code)Healthy adultsJPRN-UMIN000027062Kao Corporation15
尚未招募
2 期
To Evaluate The Effectiveness Of Sarapanga Vilvathy Legiyam In The Treatment Of Acid Peptic Disease (Eri gunmam)CTRI/2023/09/057631ot Applicable
进行中（未招募）
不适用
A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma - THYRRAD, CRAD001CNL08TPatients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus).EUCTR2009-016669-27-NLeiden University Medical Center
已完成
2 期
A phase II study to investigate the efficacy of RAD001 (Afinitor ®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinomathyroid cancerNL-OMON35047eids Universitair Medisch Centrum42